John P. Perentesis, MD, FAAP, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs and discovered genes important in the growth of normal and malignant cells. His laboratory is also using tumor patients genomics research for personalizing therapies. In national efforts for new anticancer drug development, he serves in key roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest children's cancer research entity.
In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national COG Executive Committee. He also serves as vice-chair for the COG Adolescent & Young Adult Cancer Steering Committee and as a member of the Hematology/Oncology and Institutional Performance Monitoring Steering Committees.
Dr. Perentesis has been elected by his peers for inclusion in the Best Doctors in America List since 1998.
MD: University of Michigan, Ann Arbor, MI, 1980.
Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.
Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.
Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.
Certification: Pediatrics, 1989; Hematology/Oncology, 1990.
Young adult cancers; acute myeloid & lymphoid leukemia; Hodgkin lymphoma; new anticancer therapy development
Leukemia, Sarcoma, Cancer and Blood Diseases, Young Adult Cancer
Molecular etiology and pharmacogenetics of pediatric cancers; Down syndrome-associated leukemia; new anticancer drug development
Oncology, Cancer and Blood Diseases
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatric Blood and Cancer. 2015; 62:1739-1746.
Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis. Nature. 2022; 612:787-794.
FAST-01: Results of the First-in-Human Study of Proton FLASH Radiotherapy. International Journal of Radiation Oncology Biology Physics. 2022; 114.
Cognitive and behavioral effects of whole brain conventional or high dose rate (FLASH) proton irradiation in a neonatal Sprague Dawley rat model. PLoS ONE. 2022; 17.
US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity. Pediatric Blood and Cancer. 2022; 69.
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine. 2022; 14.
Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. Leukemia. 2022; 36:637-647.
The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Leukemia. 2022; 36:438-451.
Can Rational Combination of Ultra-high Dose Rate FLASH Radiotherapy with Immunotherapy Provide a Novel Approach to Cancer Treatment?. Comparative Haematology International. 2021; 33:713-722.
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Pediatric Blood and Cancer. 2021; 68.
John P. Perentesis, MD, FAAP3/28/2023
John P. Perentesis, MD, FAAP10/24/2022
John P. Perentesis, MD, FAAP11/19/2020
John P. Perentesis, MD, FAAP6/29/2019
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey